Information Provided By:
Fly News Breaks for February 28, 2020
Feb 28, 2020 | 05:22 EDT
Piper Sandler analyst Tyler Van Buren reiterates an Overweight rating on Biohaven Pharmaceutical (BHVN) with a $100 price target after the company announced the FDA approval of quick-dissolving Nurtec ODT for the acute treatment of migraine. This is the second approval for the next generation oral CGRP class of drugs as Allergan's (AGN) Ubrelvy received approval at year-end, Van Buren tells investors in a research note. However, Nurtec's onset is around 30-60 minutes, while Ubrelvy's is 60-90 minutes, and sustained pain freedom was demonstrated out to 48 hours for Nurtec versus 24 hours for Ubrelvy, adds the analyst. He believes Nurtec "is now definitively the superior product by virtue of its superior label."
News For BHVN;AGN From the Last 2 Days
There are no results for your query BHVN;AGN